Summit Therapeutics (SMMT) Current Leases (2018 - 2026)
Summit Therapeutics' (SMMT) quarterly Current Leases came in at $3.6 million in Q2 2026, up 13.86% YoY from $3.1 million in Q2 2025, and up 11.67% on a QoQ basis from $3.2 million in Q1 2026.
Summit Therapeutics (SMMT) Current Leases (2018 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 9 years of Current Leases data on file, last reported at $3.6 million in Q2 2026.
- Quarterly Current Leases rose 13.86% year-over-year to $3.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.6 million (up 13.86% YoY) and the FY2025 annual result came in at $3.4 million, down 10.01% from the prior year.
- Current Leases grew to $3.6 million in Q2 2026, from $3.2 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $3.8 million in Q3 2024 to a low of $684000.0 in Q2 2022.
- A 5-year average of $2.7 million and a median of $3.0 million in 2023 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2022 — Current Leases sank 32.01% — and 2023, when it surged 328.07%.
- Tracing SMMT's Current Leases over 5 years: stood at $1.7 million in 2022, then jumped by 66.21% to $2.8 million in 2023, then soared by 34.03% to $3.8 million in 2024, then declined by 10.01% to $3.4 million in 2025, then rose by 4.78% to $3.6 million in 2026.
- The last three Current Leases figures came in at $3.6 million (Q2 2026), $3.2 million (Q1 2026), and $3.4 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | 3.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.55 Mn |
| Mar 31, 2026 | 3.18 Mn |
| Dec 31, 2025 | 3.39 Mn |
| Sep 30, 2025 | 2.72 Mn |
| Jun 30, 2025 | 3.12 Mn |
| Mar 31, 2025 | 3.54 Mn |
| Dec 31, 2024 | 3.77 Mn |
| Sep 30, 2024 | 3.79 Mn |
| Jun 30, 2024 | 3.69 Mn |
| Mar 31, 2024 | 3.70 Mn |
| Dec 31, 2023 | 2.81 Mn |
| Sep 30, 2023 | 2.78 Mn |
| Jun 30, 2023 | 2.93 Mn |
| Mar 31, 2023 | 1.69 Mn |
| Dec 31, 2022 | 1.69 Mn |
| Sep 30, 2022 | 1.39 Mn |
| Jun 30, 2022 | 684,000.00 |
| Mar 31, 2022 | 907,000.00 |
| Dec 31, 2021 | 1.09 Mn |
| Sep 30, 2021 | 941,000.00 |